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Background: Diabetic nephropathy (DN) is a major microvascular complication with diabetes. In China, an
estimated 34.7 percent of people diagnosed with diabetes have renal complications and a further 50 percent die of
renal failure. Hence, identification of alternative treatments for these patients should be given priority. The Shenyan
Kangfu tablet (SYKFT) is a new formulation of an existing and widely acclaimed Chinese herbal tea for treating
qi-yin deficiency syndrome. Because a considerable portion of DN patients presenting with symptoms of swelling,
fatigue and weak limbs would be diagnosed with qi-yin deficiency syndrome according to the traditional Chinese
medicine (TCM) diagnostic criteria, we hypothesize that SYKFT may represent a complementary drug for DN
patients with the corresponding syndrome. In view of this, we have designed a trial to assess the efficacy and
safety of SYKFT for patients with diabetic nephropathy exhibiting signs of qi and yin deficiency.
Methods: This is a multicenter, double-blind, randomized controlled trial (RCT). The total target sample size is
planned at 80 participants, with a balanced (1:1) treatment allocation. The experimental intervention will be SYKFY
plus irbesartan (SI regimen) and the control intervention will be a placebo plus irbesartan (PI regimen). Participants
will receive two courses of medication treatment each lasting 8 weeks. The primary outcome will be the composite
of the quantitative 24-hour urinary protein level and urinary albumin excretion rate (UAER). Changes in urine
albumin-to-creatinine ratio (UACR) and DN staging, and TCM symptom improvement will be the secondary
outcome measures. Adverse events (AEs) will be monitored throughout the trial.
Discussion: This study will be the first placebo-controlled RCT to assess whether SYKFT plus irbesartan will have
beneficial effects on enhancing overall response rate (ORR), changing DN staging, improving clinical symptoms,
and reducing the frequency of AEs for DN patients with qi-yin deficiency syndrome. The results of this trial will help
to provide evidence-based recommendations for clinicians.
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Diabetic nephropathy (DN) is renal disease or damage
that occurs in patients with diabetes [1]. The World
Health Organization defines it as a major microvascular
complication with diabetes, and a leading cause of dialysis
and kidney transplant in developed countries [2]. The
American National Diabetes Fact Sheet 2011 found DN
was liable for 44 percent of new cases of renal failure in
2008 in the United States [3]. According to a national sur-
vey conducted in 2007 and 2008, China has the world’s
largest diabetic population, with more than 92.4 million
people affected [4]. The survey also linked 34.7 percent of
the Chinese type II diabetic patients with kidney compli-
cations [4]. Moreover, the Chinese National Blueprint for
Diabetes Prevention and Control 2011 attributed the
deaths of half of all diabetes patients complicated with
kidney diseases to renal failure [5]. Early intervention is of
profound significance to mitigating clinical symptoms,
managing proteinuria and hematuria, slowing disease pro-
gression and preventing life-threatening kidney failure.
Currently, conventional treatments for DN include life-
style changes, dietary protein restriction as well as blood
pressure and blood glucose control. Antihypertensives
and drugs to reduce proteinuria, such as angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin re-
ceptor blockers (ARBs), are recommended renoprotective
medications for DN sufferers [4]. However, effective as
they are, research finds long-term medication use may
lead to a number of adverse reactions such as cough,
hypotension, hyperkalemia, exacerbated kidney function
and also have negative effects on the fetus [6]. As a result,
focus has been shifted from western medicine to trad-
itional Chinese medicine (TCM) for an effective integrated
approach to DN, with prospectively low expenses and
minimum undesired effects.
It is well known that traditional Chinese medicine
cures ailments on the basis of the signs and symptoms
of a patient [7]. This means the same group of symp-
toms is likely to be remedied with the same herbal for-
mula, regardless of the disease type (Bian zheng lun zhi
in Chinese pinyin), a therapeutic rule derived from the
wisdom of the Han dynasty herbalist Zhang Zhongjing
(A.D. 150 to 219) [7]. Shenyan Kangfu tablets (nephritis
recovery tablets, literally, hereafter referred to as
SYKFT) is a Chinese patent drug originally designated
for clinical treatment of chronic nephritis patients diag-
nosed with qi-yin deficiency syndrome (a TCM syn-
drome characterized by the lack of qi and yin energy in
the body) [8]. SYKFT has been considered for use in DN
treatment because DN patients may share the same
TCM syndrome and clinical symptoms with nephritis
sufferers. For instance, they may both display symptoms
of mental and physical fatigue, swollen face and limbs,
sore waist and weak limbs or dizziness and tinnitus, andmay both present a red tongue with little coating and a
sunken and string-like/thready pulse upon TCM tongue
and pulse diagnosis. Moreover, patients suffering from
both diseases may develop proteinuria and hematuria
with the progression of renal insufficiency. Thus we
speculate that the effective solution for the treatment of
nephritis may play a similar role in the treatment of DN.
We will conduct a multicenter, double-blind randomized
clinical trial (RCT) of SYKFT in phase III and IV DN
patients to test this hypothesis.
Objectives
This clinical trial aims to assess whether Shenyan Kangfu
tablets combined with irbesartan (SI regimen) is superior
to a placebo combined with irbesartan (PI regimen) in




This is a multicenter, randomized, double-blind and
placebo-controlled clinical trial lasting 16 weeks. The
design of the trial integrates strict and scientific clinical
research methodology in compliance with principals laid
down in the Declaration of Helsinki and the Guidelines
for Good Clinical Practice (Figure 1).
Setting
Participants will be enrolled at five trial sites in four cit-
ies in mainland China: 1) Longhua Hospital of Shanghai
University of TCM; 2) The Sixth People's Hospital of
Shanghai; 3) Guangxing Hospital Affiliated to Zhejiang
University of TCM; 4) The First Affiliated Hospital of
Tianjin University of TCM and 5) The Affiliated Hos-
pital to Liaoning University of TCM.
Participants
The study plans to enroll 80 patients diagnosed with dia-
betic nephropathy and qi-yin deficiency syndrome. They
should also meet the items of both the inclusion and ex-
clusion criteria presented in a following section.
Study criteria
Diagnostic criteria
Diagnostic criteria for DN
Stage III: early-stage diabetic nephropathy. Urinary albu-
min excretion rate (UAER) falls within the range of 20
to 200 ug/min or 30 to 300 mg/24h, accompanied by
slightly elevated blood pressure.
Stage IV: also termed clinical or dominant diabetic ne-
phropathy. This stage is featured by a large amount of
proteinuria, UAER >200 ug/min or the urinary protein
quantitative is persistently higher than 500 mg/24h, and
Patients eligible for inclusion
Randomization
Outcome assessment
Allocate to control group (PI)Allocate to intervention group (SI)
SYKFT 2.4g TID plus irbesartan 0.15 g 
QD for 16 weeks
SYKFT placebo 2.4g TID plus irbesartan
0.15 g QD for 16 weeks
Data collection Data collection
Figure 1 Study flow chart.
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vated blood pressure and symptoms of nephrotic
syndrome.Diagnostic criteria for TCM syndrome differentiation
According to the Guidelines for Clinical Research of
Chinese Medicine (New Drug) [9], a patient ought to
be currently displaying all the primary symptoms and
at least two of the several secondary symptoms listed
below to be diagnosed with qi-yin deficiency syndrome.
 Primary signs and symptoms include thirst,
increased food and water consumption, excessive
hunger and excessive urination at night.
 Secondary symptoms involve exhaustion, fatigue,
sore waist, weak legs, swelling face and limbs,
dizziness, tinnitus, shortness of breath, tiredness
of speaking, sore throat, dry mouth, cold
extremities, being upset, insomnia, low-grade
fever in the afternoon and feverish palms and
soles.
 Tongue and pulse: red tongue with little fur and
thready or weak pulse.Eligibility and ineligibility criteria
Inclusion criteria
 Men and women aged 35 to 65 years.
 Diagnosis of diabetic nephropathy, stage III to IV.
 TCM diagnosis of qi-yin deficiency syndrome.
 Provision of written informed consent by
participants or surrogates.Exclusion criteria
 Diagnosis of kidney cancer or other types of renal
damage.
 Presence of complications that might affect
observation on the curative effects of the test drug.
 Uncontrolled hypertension (blood pressure being
persistently greater than 140/90 mmHg).
 Diagnosis of type 1 diabetes mellitus.
 Presence of urinary tract infection.
 Glycated hemoglobin (HbA1c) >59 mmol/mol.
 Twenty-four-hour urinary protein >3 g, serum
albumin (ALB) <25 g/L and glomerular filtration
rate (GFR) <60 ml/min.
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hematologic or cardiovascular diseases or any other
life-threatening conditions.
 History of allergy to TCM products.
 Recent participation in another clinical trial.
 Pregnancy, lactation or those who are preparing for
pregnancy.
Other criteria
Concomitant treatments and forbidden drugs
 Use of any other Chinese medicine or western
therapy like ACEIs or ARBs to relieve symptoms of
diabetic nephropathy ought to be strictly prohibited.
 Use of medication to control other conditions of the
patients, such as anticoagulatory or lipid-lowering
drugs, is allowed.
 Details of any additional drug or therapy taken must
be recorded in the case report form (CRF). These
include drug name, dose and treatment duration.
Early suspension or termination of the trial will occur
in the following situations:
 Occurrence of serious adverse events, flawed
protocol or significant deviation in implementation.
 Funding or management problems.
 The administrative authorities decide to terminate
the study.
Patients will be withdrawn or be rejected for further
participation on the grounds below:
 Voluntarily quitting.
 Use of forbidden medication or treatment during
the trial that might affect analysis of results.
 Early termination of the process based on the
investigator’s judgment (in the case of misdiagnosis,
development of severe complications, and so on.).
 Failure to keep the patient blinded, or deblinding in
case of emergency.
Exit criteria corresponding to treatment failure
 Uncontrolled blood pressure.
 HbA1C levels >59 mmol/mol.
 Uncontrolled blood glucose.
 Persistently elevated proteinuria.
Interventions
Participants randomized to the treatment group will be
administered SYKFT 2.4 g three times daily plus irbe-
sartan 0.15 g once daily for 16 weeks. Those in the con-
trol group will receive SYKFT placebo 2.4 g three timesdaily in addition to irbesartan 0.15 g once daily for 16
weeks. Both groups will receive behavioral intervention
and health education such as diet instructions. All test
drugs, that is SYKFT, the placebo and irbesartan (trade
name: Anbowei in Chinese pinyin) are manufactured by
Tianjin Tongrentang Pharmaceuticals.
Measurement items and time points of data collection
Relevant examinations will be performed and patient
data will be collected at 2 weeks before baseline, at base-
line, at 2 weeks post baseline and every 4 weeks from 4
to 16 weeks during treatment. Items to be measured and




The primary outcome of this trial will be the composite
of the quantitative 24-hour urinary protein levels and
urinary albumin excretion rate (UAER).
Secondary outcomes
Secondary outcomes include changes in urine albumin-
to-creatinine ratio (UACR), TCM symptom improve-
ment and changes in diabetic nephropathy staging (for
example, from phase III to IV).
Safety outcomes
Adverse events will be monitored throughout the trial
and several biological indicators (routine blood and
urine test, stool routine test, electrocardiogram (ECG),
liver function and blood coagulation) will also be closely
watched.
Measurement tools
Measurement scale for TCM symptoms
The measurement scale for TCM symptoms recommen-
ded by the Guidelines for Clinical Research of Chinese
Medicine (New Drug) [9] will be used for ease of assess-
ment. Each of the primary symptoms necessary for the
diagnosis of qi-yin deficiency syndrome will be scored 0,
2, 4 or 6, while a secondary symptom is scored 0, 1, 2 or
3, and the scores then summed to yield a total score of
both types of symptoms for a patient. It is stipulated that
the total primary symptom score shall not exceed 18,
and the total score for secondary symptoms shall not ex-
ceed 33 for an individual patient.
Efficacy assessment tools
For TCM symptoms
Following the Guidelines for Clinical Research of Chinese
Medicine (New Drug) [9], the reduction in the total TCM
symptom score of the patient will be calculated and used
as an efficacy indicator (EI) for the evaluation of treatment
Table 1 Measurement items and point of data capture
Screening Baseline Treatment
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7
Items −2 weeks 0 weeks 2 weeks 4 weeks 8 weeks 12 weeks 16 weeks
Informed consent form X
Inclusion/exclusion criteria X
Demographic information X
Medical/drug use history X
Concomitant disease and treatment X
General physical examination X
Combined medication X X X X X X X
Vital signs X X X X X X X
TCM symptom X X X X X X X
Urine protein test X X X X X X X
Routine urine test X X X X X X X
Renal function (SCR, BUN, GFR) Serum
albumin
X X X X
Routine blood test X X X
Stool routine test and fecal occult blood test X X X
Liver function (ALT/AST/GGT/TBIL/ALB) X X X
Blood electrolytes X X X X
Blood coagulation (TT/APTT/PT/FIB) X X X
Blood glucose X X X X X X X
Glycosylated hemoglobin X X X
Electrocardiogram (EGG) X X X
Adverse events X X X X X X X
Randomization X
Drug distribution X X X X X X
Drug recycling X X X X X X
Drug count X X X X X X
Research conclusion X
X: Have indicators tested in the specific time period. ALB, serum albumin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST,
aspartate aminotransferase; BUN, blood urea nitrogen; FIB, fibrinogen; GFR, glomerular filtration rate; GGT, gamma-glutamyl transpeptidase; PT, prothrombin time;
SCR, serum creatinine; TBIL, total bilirubin; TCM, traditional Chinese medicine; TT, thrombin time.
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formula:
EI ¼ Total symptom score at baseline
−Total symptom score post treatmentÞ=
Total symptom score at baseline 100%
The degree of symptom improvement will be presented
in four categories ranging from ‘full recovery’ (EI ≥90%),
‘good recovery’ (90% >EI ≥70%), ‘modest recovery’ (70%
>EI ≥30%) to ‘no recovery’ (EI <30%).
For laboratory indicators of the disease
Full recovery (FR): the quantitative 24-hour urinary pro-
tein, UAER and renal function return to normal levels.Good recovery (GR): a decrease of ≥40% in UAER or
the quantitative 24-hour urinary protein.
Modest recovery (MR): a decrease of <40% in UAER
or the quantitative 24-hour urinary protein.
No recovery (NR): unchanged or worsened laboratory
test results.
To assess efficacy with regard to either TCM symp-
tom improvement or amelioration of clinical signs, an
overall recovery rate (ORR) will be calculated using
the following formula.
ORR ¼ FR countþ GR countþMR countð Þ=
Group population 100%:
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Adverse events (AEs) will be recorded in medical diag-
nostic terminology. Detailed symptoms, time of occur-
rence, duration, severity, possible causal relationships,
actions taken, results and other relevant information will
be reported. In the case of an adverse event, researchers
must fill out a serious adverse event (SAE) form and no-
tify both the institutional review board (IRB) and the
regulatory authorities within 24 hours.
Sample size calculation
This is an exploratory phase II clinical study designed to
provide evidence and a scientific rationale for advancing
the treatment regimen into a phase III confirmatory study.
The planned sample size is 80, with 40 in each treatment
group.
Randomization and allocation concealment
A total of 80 patients will be randomly assigned in a ratio
of 1:1 to either the SI or the PI group using a computer-
generated random number sequence. To guarantee rigor-
ous methodology, center-stratified randomization and
central coordination will be initiated. The central rando-
mization system will assign a unique code to each newly
included participant, who will then be administered the
corresponding treatment regimen.
An expert statistician of the Tianjin Institute of Clinical
Evaluation and a staff member from the sponsoring
organization will act as the coder, and they will be shielded
from patient recruitment. The trial management board
will be responsible for keeping the blinding codes and
other information confidential.
Blinding
This trial will use the double-blind design. The placebo
tablets are indistinguishable from SYKFT in shape, size,
color and packaging. Thus, both participants and clini-
cians will be masked. Moreover, a designated pharmacist
not involved with the study will be held responsible for
handing out medication.
Statistical analysis
The statistical analysis will be performed by a statistician
with the Tianjin Institute of Clinical Evaluation, and the
data will be analyzed using Statistical Analysis System
(SAS) software version 9.2 (SAS Institute Inc., Cary, NC,
USA). A formal and detailed statistical analysis plan will
be documented prior to data locking.
Efficacy assessment
All primary analyses for this study will strictly follow the
intention-to-treat (ITT) principle. The full analysis set
(FAS) population, which will include randomized subjects
who have received treatment at least once, will be used forprimary efficacy outcomes analysis. In addition, a per-
protocol analysis will be performed on the secondary
outcomes. The per-protocol set (PPS) population will be
restricted to patients who are compliant with the treatment
protocol and have a completed CRF. Good compliance in-
dicates the drug actually taken equals 80 to 120 percent of
the required dosage. Missing values will be replaced using
the last observation carried forward (LOCF) method.
Continuous variables will be described as mean ± stand-
ard deviation, and dichotomous data will be reported as
percentages. A two-tailed test will be applied. Statistical
significance will be defined as P <0.05 and 95% confidence
interval will be calculated. Heterogeneity between groups
will be tested at baseline.
The main analysis will be a comparison between the
two groups concerning the proportion of patients achiev-
ing different levels of recovery (FR, GR, MR or NR) in
terms of TCM symptoms and clinical biomarkers using
the Wilcoxon rank sum test. In addition, the ORR will be
compared between the two arms using the center-
stratified Cochran-Mantel-Haenszel (CMH) method. For
secondary outcomes, all continuous data will be analyzed
via analysis of covariance adjusted for clinical center and
baseline. Analyses of binary data will be based on logistic
regression models.
Safety assessment
The safety set (SS) population, which will include ran-
domized subjects who have made at least one visit, will
be used for safety analysis. The frequency of adverse
events and incidence of abnormalities in laboratory tests
before and after treatment will be compared for the two
groups using a chi-squared test. Any possible causal re-
lationship between the test drug and the abnormality
will be detected using an appropriate statistical model
Management of test drugs
Drug packaging
To ensure effective blinding, SYKFT and the placebo will
be prepared respectively but uniformly packaged. On the
outside of the package, the drug code, name, specifica-
tions, function and indications, usage and dosage, stor-
age conditions and name of the manufacturer will be
specifically marked and a tag indicating ‘for trial use
only’ will be attached.
Storing, handing out and reclaiming of test drug
A drug administrator will be assigned at each center,
who will be responsible for the storage, handing out and
reclaiming of the test drug. They shall make sure the test
drug is kept in a dry, ventilated place and at the appropri-
ate temperature. The test drug will be dispensed during
the treatment period and reclaimed at study completion.
The drug administrators should return unused drugs to
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struction, they should make records and file a ‘Certifica-
tion of Test Drug Destruction’.
Quality control of data
Quality control of the research data will be achieved by
rigorous monitoring throughout the trial process. Trial
monitors will pay regular visits to each site, where they
will recheck CRFs, inspect the storage of the investiga-
tional drugs and review investigators’ records. After veri-
fication of the content of the written CRFs, data will be
collected and inputted into a database by two full-time
research staff independently. The standard operating
procedures (SOP) will be invariably followed.
Ethics issue
This study has been approved by the IRBs of each partici-
pating hospital, and is registered at ChiCTR (www.chictr.
org, trial identifier ChiCTR-TRC-12002182). It will be
made sure only clinicians holding the necessary qualifica-
tions act as principal investigators. Written informed con-
sent will be obtained from individual participants prior to
enrollment.
Discussion
SYKFT is an improved version of the herbal prescription
based on the valuable therapeutic knowledge of the late
TCM practitioner Zhao Enjian, who had enjoyed nation-
wide fame for treating patients with chronic nephritis
[10]. The formula is a combination of 11 herbal ingredi-
ents with a synergic effect of tonifying qi and yin, nourish-
ing the kidney and spleen and detoxicating the body [11].
The tablet formulation is manufactured by Tianjin
Tongrentang Pharmaceuticals (Register No: Z10940034)
and film-coated tablets are now available for diabetes pa-
tients [10]. SYKFT is recommended for treating a variety
of indications including fatigue, waist pain, swollen face
and limbs, dizziness, tinnitus, proteinuria and hematuria.
Preclinical study evidences that SYKFT has curative ef-
fects on streptozotocin-induced diabetic rats with unilat-
eral nephrectomy [12]. Another research study finds the
drug’s renoprotective effect is associated with the
upregulation of podocalyxin expression in DN mouse
models [13]. The chronic toxicity test with an observa-
tion period of six months reported no death and no
abnormal pathological changes in the experimental ani-
mals [unpublished data, Tianjin Institute of Medical and
Pharmaceutical Science]. Also, SYKFT has been reported
to have improved symptoms, controlled proteinuria and
retarded the progression of renal failure for DN patients
in clinical observations and preliminary trials [14-22].
In view of the current evidence base, we have designed
this placebo-controlled RCT to test the efficacy and safety
of SYKFT for diabetic nephropathy patients with qi-yindeficiency syndrome. The findings of this study will in-
form hypothesized effects of SYKFT and may provide an
alternative treatment option for diabetic nephropathy. It
will also provide evidence and a scientific rationale for
advancing the treatment regimen into a phase III con-
firmatory study.
Trial status
The trial was initiated in November 2012 and is cur-
rently open for enrollment. A total of 20 participants
had been enrolled and randomized for this trial by
March 2013.
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